New Hope for
Brain Injuries
Algernon is the first company
in the world to investigate
psychedelic DMT for stroke
and traumatic brain injury
Overview
Invest
The Potential of DMT
DMT is a natural psychedelic that
may promote neuroplasticity in
the brain after injuries like
concussion and stroke
Pipeline
Brain Derived
Neurotropic Factor
DMT increases brain derived
neurotropic factor (BDNF), which
is critical to healing after a stroke
or traumatic brain injury
Pipeline
Human Studies Underway
DMT intravenous dose and duration studies are now being conducted
with Phase 2 studies being planned for Fall 2023
Clinical Trials
World's Leading
Specialists
We have leading DMT, stroke
and traumatic brain injury
experts on our team
Program Advisors
There is a Huge Global
Market for Treatment
Stroke Treatment Market = USD $15B TBI Treatment Market = USD $4.5B
Invest
Participate in Discovery
and Innovation
Be part of our ground-breaking
brain recovery research and invest
in Algernon NeuroScience today
Overview
Invest